EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

C–C Motif chemokine receptor-2 blockade ameliorates pulmonary hypertension in rats and synergizes with a pulmonary vasodilator

Naoki Tsuboya iD, Hirofumi Sawada, Yoshihide Mitani iD, Hironori Oshita, Kazunobu Ohya, Mami Takeoka iD, Jane Chanda Kabwe, Yoshiki Miyasaka, Hiromasa Ito, Noriko Yodoya, Hiroyuki Ohashi, Junko Maruyama und 6 weitere

Cardiovascular Research · 2025

DOI: 10.1093/cvr/cvae244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2025. Verfasst von Naoki Tsuboya und 17 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Pediatrics, Mie University Graduate School of Medicine, Mie, Japan. Hauptthemen laut MEDLINE: Receptors, CCR2, Pulmonary Artery, Vasodilator Agents, Indoles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Contracted Research Grants from Janssen Pharmaceutical K.K.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We investigated whether the disruption of C–C motif chemokine receptor (CCR) 2 may attenuate the development of pulmonary arterial hypertension (PAH) in any rat models with the reversal of the associated pro-inflammatory state and vascular dysfunction, and synergize with a conventional pulmonary vasodilator. Methods and results Using Ccr2(−/−) rats generated by CRISPR/Cas9, we investigated pulmonary hypertension (PH) in Ccr2(+/+) or Ccr2(−/−) rats treated with monocrotaline (MCT), SU5416/hypoxia (SuHx) and chronic hypoxia (CH). Ccr2(−/−) decreased the right ventricular systolic pressure, an index of right ventricular hypertrophy and mortality rate, and reversed increased expression of inflammatory cytokines/chemokines [interleukin-6, tumour necrosis factor-α, C–C motif chemokine receptor (CCL)-2, interleukin-1β, transforming growth factor-β] in rats 3weeks after MCT injection, but not in SuHx or CH models. Consistently, Ccr2(−/−) decreased indices of pulmonary vascular diseases (PVDs) and perivascular macrophage infiltration, as well as reversed impaired bone morphogenetic protein receptor type 2 signalling, increased endothelial apoptosis and impaired nitric oxide signalling and decreased phosphodiesterase-5 (PDE5) expression in lungs in MCT-treated rats. Gene expression of receptors for prostaglandin I2 and endothelin was not changed by Ccr2(−/−) in MCT-treated rats. In cultured pulmonary arterial smooth muscle cells (PASMCs), Ccr2(−/−) suppressed CCL2-induced hyperproliferation and dedifferentiation as well as reversed CCL2-induced decrease in PDE5 expression. The whole-genome RNA sequencing analysis identified differentially expressed genes in CCL2-stimulated Ccr2(−/−) PASMCs, which are related to the regulation of cellular differentiation and contraction. Based on studies in rats and cultured PASMCs, we investigated whether a PDE5 inhibitor, tadalafil, synergizes with Ccr2(−/−). Tadalafil administration ameliorated PH and PVDs in MCT-treated Ccr2(−/−) rats but not in Ccr2(+/+) rats. Tadalafil further improved survival in MCT-treated Ccr2(−/−) rats.

Conclusion

The present findings demonstrated that CCR2 disruption ameliorated PAH in MCT-treated rats, which was associated with the reversal of dysregulated inflammatory pathways and vascular dysfunction and synergized with tadalafil. These findings suggest that CCR2 may be a therapeutic target in intractable PAH patients with a certain CCR2-related inflammatory phenotype and refractory to conventional pulmonary vasodilators.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CCR2Pulmonary ArteryVasodilator AgentsIndolesPulmonary Arterial HypertensionHypertension, PulmonaryArterial PressureVasodilationPhosphodiesterase 5 InhibitorsAnimalsDisease Models, AnimalMaleCells, CulturedMuscle, Smooth, VascularSignal TransductionPyrrolesMyocytes, Smooth MuscleMonocrotalineVascular RemodelingRats, Sprague-DawleyInflammation MediatorsHypertrophy, Right VentricularVentricular Function, RightRatsCytokinesBone Morphogenetic Protein Receptors, Type IICell ProliferationHypoxiaCyclic Nucleotide Phosphodiesterases, Type 5

Stichwörter der Autor:innen

Combination therapyC–C Chemokine receptor type 2InflammationPulmonary hypertension

Substanzen

Receptors, CCR2Vasodilator AgentsCcr2 protein, ratSemaxinibIndolesPyrrolesMonocrotalineInflammation MediatorsCytokinesBone Morphogenetic Protein Receptors, Type II

Autor:innen und Institutionen

  • The Department of Pediatrics, Mie University Graduate School of Medicine, Mie, Japan.
  • The Department of Pediatrics, Nagoya City University School of Medicine, Aichi, Japan.
  • The Department of Anesthesiology and Critical Care, National Heart Hospital, Lusaka, Zambia.
  • Institute of Experimental Animal Sciences, Osaka University Graduate School of Medicine, Osaka, Japan.
  • The Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Mie, Japan.
  • The Department of Clinical Engineering, Suzuka University of Medical Science, Mie, Japan.

ORCID-Profile: Naoki Tsuboya, Yoshihide Mitani, Mami Takeoka, Ryuji Okamoto

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology
  • Contracted Research Grants from Janssen Pharmaceutical K.K

Zitieren

APA

Tsuboya, N., Sawada, H., Mitani, Y., Oshita, H., Ohya, K., Takeoka, M., Kabwe, J. C., Miyasaka, Y., Ito, H., Yodoya, N., Ohashi, H., Maruyama, J., Okamoto, R., Mashimo, T., Dohi, K., Nishimura, Y., Maruyama, K., & Hirayama, M. (2025). C–C Motif chemokine receptor-2 blockade ameliorates pulmonary hypertension in rats and synergizes with a pulmonary vasodilator. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae244

Vancouver

Tsuboya N, Sawada H, Mitani Y, Oshita H, Ohya K, Takeoka M, et al. C–C Motif chemokine receptor-2 blockade ameliorates pulmonary hypertension in rats and synergizes with a pulmonary vasodilator. Cardiovascular Research. 2025. doi:10.1093/cvr/cvae244

BibTeX
@article{Tsuboya2025,
  author = {Tsuboya, Naoki and Sawada, Hirofumi and Mitani, Yoshihide and Oshita, Hironori and Ohya, Kazunobu and Takeoka, Mami and Kabwe, Jane Chanda and Miyasaka, Yoshiki and Ito, Hiromasa and Yodoya, Noriko and Ohashi, Hiroyuki and Maruyama, Junko and Okamoto, Ryuji and Mashimo, Tomoji and Dohi, Kaoru and Nishimura, Yuhei and Maruyama, Kazuo and Hirayama, Masahiro},
  title = {C–C Motif chemokine receptor-2 blockade ameliorates pulmonary hypertension in rats and synergizes with a pulmonary vasodilator},
  journal = {Cardiovascular Research},
  year = {2025},
  doi = {10.1093/cvr/cvae244}
}
Kostenlos starten →